Fleury SA
BOVESPA:FLRY3
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.14
18.04
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Fleury SA
Fleury SA
Revenue
Fleury SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fleury SA
BOVESPA:FLRY3
|
Revenue
R$7.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
|
Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
|
Revenue
R$5.5B
|
CAGR 3-Years
39%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Centro de Imagem Diagnosticos SA
BOVESPA:AALR3
|
Revenue
R$1.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
D
|
Diagnosticos da America SA
BOVESPA:DASA3
|
Revenue
R$15B
|
CAGR 3-Years
15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
Fleury SA
Glance View
Fleury SA, originally founded in 1926, stands as a paragon of healthcare excellence in Brazil, evolving over nearly a century into a leading provider of medical diagnostics and integrated healthcare services. Driven by a culture of innovation and customer commitment, the company operates a network of strategically located diagnostic centers, offering a comprehensive array of tests, from basic blood work to sophisticated imaging. At the core of Fleury's operations is their ability to seamlessly blend cutting-edge technology with medical expertise, enabling them to deliver accurate diagnostics and personalized healthcare solutions. This approach not only enhances patient experiences but also fortifies their position in a highly competitive marketplace. In generating revenue, Fleury SA capitalizes on its robust infrastructure and premium service quality. The company’s business model thrives on a vast portfolio of diagnostic services, catering to an array of clientele — from individuals seeking routine checks to physicians requiring specialized analyses. Additionally, Fleury extends its reach through partnerships with hospitals and clinics, further solidifying its reputation and reliability. By maintaining a focus on operational efficiency and strategic expansions, the company ensures steady cash flows, which in turn are reinvested into technological advancements and service enhancements. This, coupled with their focus on high-quality client relations, fuels Fleury’s ability to retain a loyal customer base and sustain its financial growth trajectory.
See Also
What is Fleury SA's Revenue?
Revenue
7.5B
BRL
Based on the financial report for Sep 30, 2024, Fleury SA's Revenue amounts to 7.5B BRL.
What is Fleury SA's Revenue growth rate?
Revenue CAGR 10Y
16%
Over the last year, the Revenue growth was 28%. The average annual Revenue growth rates for Fleury SA have been 26% over the past three years , 16% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet